2016 Nov 11
Anticipated METRIC results could lead to first targeted agent approved in TNBC
Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer (TNBC), explains Linda T. Vahdat, M.D. Read more